Loading...
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such therapies. A recen...
Na minha lista:
| Udgivet i: | Genome Med |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5080691/ https://ncbi.nlm.nih.gov/pubmed/27782862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-016-0365-1 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|